WallStreetZenWallStreetZen

NASDAQ: RNAZ
Transcode Therapeutics Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Transcode Therapeutics earnings were -$16.8M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. The latest RNAZ earnings report on Dec 31, 2024 announced Q4 2024 earnings of -$5.9M, up 156.2% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, RNAZ reported annual earnings of -$16.8M, with -9.5% growth.

RNAZ earnings history

Current Revenue
$0.0
Current Earnings
-$16.8M
Current Profit Margin
0%

RNAZ Return on Equity

Current Company
-1,212%
Current Industry
-2%
Current Market
34.1%
RNAZ's Return on Equity (-1,212%)... subscribe to Premium to read more.
High Return on Equity Performance

RNAZ undefined

Current Company
-287.6%
Current Industry
-0.4%
RNAZ is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when RNAZ announces earnings.

RNAZ undefined

Current Company
-369.87%
Current Industry
5.9%
RNAZ's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

RNAZ vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
RNAZ-$16.19M-$16.79MN/A-$16,785,572.00
ACXP-$14.10M-$14.10MN/A-$0.87
APRE-$14.23M-$12.96MN/A-$2.35
CYCN-$3.06M-$3.06MN/A-$1.21
KPRX$5.75M$3.59MN/A$0.93
View Top Biotech Stocks

Transcode Therapeutics Earnings Reports & History FAQ

What were Transcode Therapeutics's earnings last quarter?

Transcode Therapeutics (NASDAQ: RNAZ) reported Q4 2024 earnings per share (EPS) of -$16,785,532.07, up 9.45% year over year. Total RNAZ earnings for the quarter were -$5.95 million. In the same quarter last year, Transcode Therapeutics's earnings per share (EPS) was -$18,537,064.22.

If you're new to stock investing, here's how to buy Transcode Therapeutics stock.

Is Transcode Therapeutics profitable or losing money?

As of the last Transcode Therapeutics earnings report, Transcode Therapeutics is currently losing money. Transcode Therapeutics's net profit (also called net income) for the twelve months ending Dec 31, 2024 was -$16.75 million, a 9.66% decrease year over year.

What was RNAZ's earnings growth in the past year?

As of Transcode Therapeutics's earnings date in Q2 2025, Transcode Therapeutics's earnings has grown year over year. RNAZ earnings in the past year totalled -$16.79 million.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.